Novel anticancers and dermatological adversities: old rivals but new challenges

BMJ Case Rep. 2018 Dec 14;11(1):e227790. doi: 10.1136/bcr-2018-227790.

Authors

Kamal Kant Sahu¹, Ajay Mishra¹, Iryna Chastain¹

Affiliation

¹ Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.

No abstract available

Keywords: cancer; cancer intervention; chemotherapy; dermatology; immunology.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung / complications
Adenocarcinoma of Lung / diagnostic imaging
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / pathology
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Drug Eruptions / etiology*
Drug Eruptions / pathology
Humans
Lung Neoplasms / complications
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Neoplasm Staging
Pemetrexed / administration & dosage
Pleural Effusion, Malignant / diagnostic imaging
Pleural Effusion, Malignant / etiology

Substances

Antibodies, Monoclonal, Humanized
Pemetrexed
pembrolizumab